- Home
- CAPT vs BOLT Comparison
CAPT vs BOLT Comparison
Compare CAPT & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPT
- BOLT
- Stock Information
- Founded
- CAPT 2005
- BOLT 2015
- Country
- CAPT South Korea
- BOLT United States
- Employees
- CAPT N/A
- BOLT N/A
- Industry
- CAPT Blank Checks
- BOLT Biotechnology: Pharmaceutical Preparations
- Sector
- CAPT Finance
- BOLT Health Care
- Exchange
- CAPT Nasdaq
- BOLT Nasdaq
- Market Cap
- CAPT 16.0M
- BOLT 16.8M
- IPO Year
- CAPT N/A
- BOLT 2021
- Fundamental
- Price
- CAPT $1.54
- BOLT $6.19
- Analyst Decision
- CAPT
- BOLT Buy
- Analyst Count
- CAPT 0
- BOLT 3
- Target Price
- CAPT N/A
- BOLT $50.00
- AVG Volume (30 Days)
- CAPT 357.6K
- BOLT 18.8K
- Earning Date
- CAPT 01-01-0001
- BOLT 08-12-2025
- Dividend Yield
- CAPT N/A
- BOLT N/A
- EPS Growth
- CAPT N/A
- BOLT N/A
- EPS
- CAPT N/A
- BOLT N/A
- Revenue
- CAPT $17,389,944.00
- BOLT $3,638,000.00
- Revenue This Year
- CAPT N/A
- BOLT N/A
- Revenue Next Year
- CAPT N/A
- BOLT $24.14
- P/E Ratio
- CAPT N/A
- BOLT N/A
- Revenue Growth
- CAPT 84.70
- BOLT N/A
- 52 Week Low
- CAPT $0.37
- BOLT $5.20
- 52 Week High
- CAPT $2.88
- BOLT $15.60
- Technical
- Relative Strength Index (RSI)
- CAPT 71.95
- BOLT 52.70
- Support Level
- CAPT $1.14
- BOLT $5.68
- Resistance Level
- CAPT $1.21
- BOLT $6.40
- Average True Range (ATR)
- CAPT 0.08
- BOLT 0.30
- MACD
- CAPT 0.02
- BOLT 0.09
- Stochastic Oscillator
- CAPT 86.54
- BOLT 79.81
About CAPT Captivision Inc.
Captivision Inc Formerly Glaam Co Ltd is engaged in manufacturing, installing, and selling LED display G-Glass. G-Glass is an integrated ICT product that has the basic characteristics of transparent glass but can display media images at the same time. It implements media images through the glass surface while preserving the features of clear and transparent glass. G-Glass is the world's first IT building material that can be applied to various places where glass is used.
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on our deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.